Improving Patient Lives with Single Cell Precision
HiFiBiO Therapeutics, a clinical-stage global biotech, is pioneering a unique high-resolution translational platform (DIS®) to enhance the probability of success for immunotherapies
HiFiBiO Therapeutics, a clinical-stage global biotech, is pioneering a unique high-resolution translational platform (DIS®) to enhance the probability of success for immunotherapies
Our Science
We apply single cell science at every stage of drug development from target discovery to predictive biomarkers, enabling rapid advancement of new therapeutics into the clinic.
Read moreOur SOAR Values
We unite under a shared mission to SOAR to new heights in science and healthcare.
Read moreCAMBRIDGE, MA., – January 7, 2024 – HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with Nasdaq Live from MarketSite to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies by gaining an unprecedented understanding of immune dysregulation at the single cell level. HiFiBiO’s unique high-resolution translational DIS® platform enhances the probability … Continued
Paris, France, and Cambridge, MA, December 11, 2023 – HiFiBiO Therapeutics, a leading clinical stage global biotech company dedicated to advancing patient outcomes through single-cell precision, proudly announces its strategic collaboration with clinical institutions and life science companies in the formation of a groundbreaking consortium under the France 2030 Initiative. This visionary project, named REMISSION … Continued
Cambridge, MA, November 8, 2023 – HiFiBiO Therapeutics, a clinical stage global biotech company with the goal of improving patient lives with single-cell precision, today announced that BioTech Breakthrough has named its proprietary translational platform, Drug Intelligence Science (DIS®) as the BioTech AI Innovation of the Year. The annual awards program features the best and … Continued
CAMBRIDGE, MA., – January 7, 2024 – HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with Nasdaq Live from MarketSite to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies by gaining an unprecedented understanding of immune dysregulation at the single cell level. HiFiBiO’s unique high-resolution translational DIS® platform enhances the probability … Continued
HiFiBiO Therapeutics single-cell focused platform identifies translationally relevant targets, enables rapid drug development, and matches treatments to patients for better clinical outcomes